These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28940329)

  • 1. US Food and Drug Administration approves first cancer treatment for any solid tumors with specific biomarker.
    Cancer; 2017 Oct; 123(19):3652-3653. PubMed ID: 28940329
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019.
    Chen EY; Haslam A; Prasad V
    JAMA Intern Med; 2020 Jun; 180(6):912-914. PubMed ID: 32338703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers.
    Prasad V; Kaestner V; Mailankody S
    JAMA Oncol; 2018 Feb; 4(2):157-158. PubMed ID: 29285544
    [No Abstract]   [Full Text] [Related]  

  • 4. Approvals in 2018: a histology-agnostic new molecular entity, novel end points and real-time review.
    Blumenthal GM; Pazdur R
    Nat Rev Clin Oncol; 2019 Mar; 16(3):139-141. PubMed ID: 30670830
    [No Abstract]   [Full Text] [Related]  

  • 5. Cutting-edge cancer drug hobbled by diagnostic test confusion.
    Ledford H
    Nature; 2018 Apr; 556(7700):161-162. PubMed ID: 29636574
    [No Abstract]   [Full Text] [Related]  

  • 6. While We're at It, Let's Whack the FDA.
    Chabner BA
    Oncologist; 2016 Mar; 21(3):259-60. PubMed ID: 26869585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are european cancer patients getting a fair deal?
    McVie JG
    Ann Oncol; 2001 Aug; 12(8):1033-5. PubMed ID: 11583176
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug approvals 2011: focus on companion diagnostics.
    Goozner M
    J Natl Cancer Inst; 2012 Jan; 104(2):84-6. PubMed ID: 22215850
    [No Abstract]   [Full Text] [Related]  

  • 9. Tissue-agnostic cancer drug pipeline grows, despite doubts.
    Garber K
    Nat Rev Drug Discov; 2018 Apr; 17(4):227-229. PubMed ID: 29520093
    [No Abstract]   [Full Text] [Related]  

  • 10. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.
    Boyiadzis MM; Kirkwood JM; Marshall JL; Pritchard CC; Azad NS; Gulley JL
    J Immunother Cancer; 2018 May; 6(1):35. PubMed ID: 29754585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Does oncology change its paradigm? The challenge of agnostic approval of new therapies.].
    Martini N
    Recenti Prog Med; 2018 Jun; 109(6):317-318. PubMed ID: 29968857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.
    Seligson ND; Knepper TC; Ragg S; Walko CM
    Clin Pharmacol Ther; 2021 Feb; 109(2):334-342. PubMed ID: 32535906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials.
    Tibau A; Molto C; Borrell M; Del Paggio JC; Barnadas A; Booth CM; Amir E
    JAMA Oncol; 2018 Nov; 4(11):1610-1611. PubMed ID: 30267037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives.
    Kourie HR; Awada G; Awada A
    Immunotherapy; 2017 Jun; 9(8):647-657. PubMed ID: 28653570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncology approvals in 2020: a year of firsts in the midst of a pandemic.
    Amiri-Kordestani L; Pazdur R
    Nat Rev Clin Oncol; 2021 Mar; 18(3):129-130. PubMed ID: 33514911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant trials could speed up drug approvals.
    Peres J
    J Natl Cancer Inst; 2014 Mar; 106(3):dju072. PubMed ID: 24610911
    [No Abstract]   [Full Text] [Related]  

  • 17. Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals.
    Kim C; Prasad V
    JAMA Intern Med; 2015 Dec; 175(12):1992-4. PubMed ID: 26502403
    [No Abstract]   [Full Text] [Related]  

  • 18. Early accelerated approval for highly targeted cancer drugs.
    Chabner BA
    N Engl J Med; 2011 Mar; 364(12):1087-9. PubMed ID: 21428763
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA approves new drug for specific type of advanced breast cancer.
    Mayo Clin Womens Healthsource; 2007 Oct; 11(10):3. PubMed ID: 18418907
    [No Abstract]   [Full Text] [Related]  

  • 20. The great biomarker chase.
    Mortkowitz L
    Am J Manag Care; 2012 Feb; 18(1 Spec No.):SP22-3. PubMed ID: 22468869
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.